Pharmacokinetics and Metabolism of Melflufen, an Alkylating Peptide–Drug Conjugate, in Patients with Relapsed Refractory Multiple Myeloma

• Published in: Journal of clinical pharmacology 2024-02, Vol.64 (2), p.240-252
• Main Authors: Huledal, Gunilla, Ruiz‐Garcia, Ana, Kawakatsu, Sonoko, Wang, Xiaoning, Sjöberg, Per, Gullbo, Joachim, Pekar, David, Norin, Stefan, Jerling, Markus
• Format: Article
• Language: English
• Subjects: Alkylating agents; Alkylating Agents - therapeutic use; alkylator; Blood cells; Body weight; Cell membranes; Glomerular filtration rate; Humans; in-vitro metabolism; Lipophilic; melflufen; Melphalan; Melphalan - pharmacokinetics; Melphalan - therapeutic use; Metabolism; Metabolites; Multiple myeloma; Multiple Myeloma - drug therapy; peptide-drug conjugate; Peptides; Pharmacokinetics; Phenylalanine - analogs & derivatives; population pharmacokinetics; Population studies; relapsed refractory multiple myeloma; Tumor cells
• ISSN: 0091-2700; 1552-4604; 1552-4604
• DOI: 10.1002/jcph.2355

Melphalan flufenamide (melflufen) is a novel lipophilic peptide–drug conjugate recently approved in the European Union and the United Kingdom for the treatment of relapsed refractory multiple myeloma. Melflufen rapidly crosses the cell membrane, and inside tumor cells, melflufen utilizes peptidases and esterases to release entrapped hydrophilic metabolites with alkylating activity. In vitro, in whole blood, melflufen was rapidly distributed into blood cells and quickly converted to its main metabolite melphalan, with maximum cellular concentrations of noncovalently bound melflufen and melphalan after 1 and 6 minutes, respectively. Melphalan outflow from blood cells was slow, with peak concentrations in plasma after 25 minutes. The pharmacokinetics of melflufen was best described by a 2‐compartment model. Following a 30‐minutes intravenous infusion of 40 mg in 27 patients with relapsed refactory multiple myeloma, mean half‐life in the α phase of the curve was 1.24 minutes, half‐life in the β phase of the curve 26.7 minutes, and clearance 13.4 L/min. Desethyl‐melflufen exposure was below 20% compared to melflufen. Based on population analysis (298 patients with relapsed refactory multiple myeloma), the melphalan pharmacokinetics were well characterized by a 3‐compartment model with melflufen dosing into a peripheral compartment, assuming instantaneous distribution of melflufen into cells and subsequent rapid metabolism to melphalan. Mean clearance and central and deep peripheral volumes of distribution were 22.4 L/h, 2.70 L, and 51.3 L, respectively. Clearance increased and maximum concentration decreased with increasing body weight and estimated glomerular filtration rate. In conclusion, melflufen administration differs from melphalan administration by a more rapid distribution into cells, which, in conjunction with a rapid intracellular metabolism, allows for higher maximum concentrations of alkylating agents, and by a more extensive distribution of melphalan to peripheral tissues.